Major news broke in the iPSC sector last week when Ncardia (Cologne, Germany) and Nanion Technologies (Munich, Germany) signed a joint marketing and sales promotion agreement. Under the terms of partnership, customers of the companies will get access to high-performance instrument platforms from Nanion, coupled with Ncardia’s portfolio of hiPSC-derived cardiac cell types and assay services. [Read more…]
What are stem cells used for? There are many potential uses for stem cells, from the treatment of cancer to chronic conditions, acute injuries and more. Scientists continue to perform research on stem cells to maximize their therapeutic benefits and possible contributions to the medical industry.
In this article:
- Why Are Stem Cells Important?
- What Are Stem Cells Used For in Medicine?
- What Are Stem Cells Used For in the Body?
- Why Are Stem Cells Valuable in Research?
What Are Stem Cells Used For? | Some FAQs Answered
While stem cells are important for treating people with major health issues, they are also advancing new frontiers in healthcare. [Read more…]
iPS cell research is on the rise, as clinical applications for the iPSC-derived tissues increase in number. Induced pluripotent stem cells (iPS cells) are a type of pluripotent stem cell that can be generated directly from adult cells. There are now two iPSC-derived cell therapeutic products in clinical trials, RIKEN’s iPSC-derived retinal sheets for age-related macular degeneration (AMD) and Cynata Therapeutics’ CYP-001 for graft vs. host disease (GvHD).
Kyoto University is also launching the world’s first clinical trial utilizing an iPSC-derived therapeutics for Parkinson’s disease.
iPS Cell Research
With both iPS cell research and clinical activity expanding, the market for iPSC-derived tissues is poised to experience rapid growth.
With more than 200 different cell types in the human body, a key goal of Cellular Dynamics International (CDI), a Fujifilm company, is to continue to expand the portfolio of available human iPSC-derived tissues where possible and where there is a scientific need. For example, CDI’s first-generation GABAergic iCell Neurons are inhibitory cortical neurons that recapitulate many features of human neurons.
The utility of this cell type was immediately demonstrated as an alternative model to primary animal-based neuronal preparations for assessing neurite outgrowth as well as developmental and general neuronal cytotoxicity. However, as they are a primarily inhibitory neuronal population, they provided limited utility for assessing networked neuronal electrical activity. [Read more…]
There has been tremendous activity over the last decade in the development of stem cells therapeutics, which have relied on stem cell differentiation protocols, as well as techniques for direct cell reprogramming. Today, there are over 4,700 stem cell trials registered on ClinicalTrials.gov and publications have increased dramatically in recent years, demonstrating the rapidly growing interest of the scientific community.
However, for all its promise, stem cells are yet to deliver on this therapeutic potential, and this failure appears due to various technical challenges that still need to be overcome. [Read more…]
Although there are key players in markets like the U.S., Australia, and the EU, Japan continues to accelerates its position as a hub for induced pluripotent stem cell (iPS cell) therapy with generous funding, acquisitions, and strategic partnerships.